Cognition Therapeutics (CGTX) Q4 2024 earnings summary

Executive summary

• Zervimesine demonstrated strong efficacy in Phase 2 studies for Alzheimer's disease and dementia with Lewy bodies (DLB), showing significant slowing of cognitive decline and preservation of cognition in key subgroups.

• Strategic focus shifted to late-stage trials for Alzheimer's and DLB, with all resources reallocated after concluding the dry AMD program to extend cash runway.

• Preparing final study documents for FDA submission and planning two end-of-phase II meetings for Alzheimer's and DLB in early Q2 2025.

• Actively seeking partnerships and non-dilutive funding to support upcoming registrational trials.

• Developed a novel chemical manufacturing process for zervimesine, with provisional patents filed and commercial-scale production capabilities being established.

Financial highlights

• Cash and cash equivalents at year-end 2024 were $25 million, with $50 million in obligated grant funds remaining from the NIA.

• Net loss for 2024 was $34 million, or $0.86 per share, compared to $25.8 million, or $0.86 per share, in 2023.

• Research and development expenses increased to $41.7 million in 2024 from $37.2 million in 2023, mainly due to Phase 2 trial activities.

• General and administrative expenses decreased to $12.3 million in 2024 from $13.5 million in 2023.

• Raised $12.8 million in gross proceeds through an ATM facility during 2024.

Outlook and guidance

• Sufficient cash runway to fund operations and capital expenditures into the fourth quarter of 2025 due to pipeline prioritization and cost savings.

• Plans to initiate Phase 3 clinical trials for zervimesine in DLB and Alzheimer's following FDA meetings in 2025.

• Upcoming milestones include two end-of-phase II FDA meetings and potential partnership announcements.

• Confident in regaining NASDAQ compliance within the six-month grace period granted.